Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2002
02/14/2002US20020018817 Method for treatment of asthma syndrome
02/14/2002US20020018814 Chlorhexidine formulations, new chlorhexidine salts, solutions containing these and their use
02/14/2002US20020018812 Sponge-like or foam
02/14/2002US20020018811 Application of phytosteroids(and isomers thereof), folic acid, cyanocobalamine and pyridoxine in dietetic (alimentary) fibers
02/14/2002US20020018810 Controlled release oxycodone compositions
02/14/2002US20020018809 Analgesics; rheumatic diseases; muscular disorders; sleep disorders
02/14/2002US20020018808 Vaccines against sterols
02/14/2002US20020018807 Mixture of cocoa plant extract and antichloesterol agent
02/14/2002US20020018804 Biological bioadhesive composition and methods of preparation and use
02/14/2002US20020018803 Administering racemic mixtures
02/14/2002US20020018800 Two-stage transmucosal medicine delivery system for symptom relief
02/14/2002US20020018788 Trimethylglycine compound
02/14/2002US20020018787 Synergistic mixture of dimethylglycine and mussel extract
02/14/2002US20020018782 Binding to antibodies; prophylaxis, therapy of infections
02/14/2002US20020018776 Method of treating graft rejection using inhibitors of CXCR3 function
02/14/2002US20020018772 Super absorption coenzyme Q10
02/14/2002US20020018769 Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
02/14/2002US20020018753 Mixture of drug, propellant and solvent
02/14/2002US20020018752 Ablation disease by cutting, blocking blood supply to tissue
02/14/2002US20020017305 Method of restoring endothelium of cornea
02/14/2002US20020017297 Dry powder dispersing apparatus and methods for their use
02/14/2002DE10038699A1 Mittel zur Verringrung der Abstoßungsreaktionen bei Transplantaten Means for Verringrung of rejection reactions in transplants
02/14/2002DE10038641A1 Vitamin A composition used for treating e.g. vitamin A deficiency and ophthalmological disorders includes phytol or phytol derivative to reduce teratogenic effects
02/14/2002DE10038640A1 Präparat mit gefäßschützender und antioxidativer Wirkung sowie dessen Verwendung Preparation with vascular protective and antioxidant activity and its use
02/14/2002DE10038571A1 Zusammensetzungen und Dosierungsformen zur Anwendung in der Mundhöhle bei der Bhandlung von Mykosen Compositions and dosage forms for use in the oral cavity in Bhandlung mycoses
02/14/2002DE10037982A1 New laccaridione compounds useful as protease inhibitors, e.g. for treating cancer, autoimmune diseases and allergies
02/14/2002DE10036871A1 Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe Dispersions for the formulation of poorly soluble drugs or little
02/14/2002DE10035991A1 Nagellackzusammensetzung Nail polish composition
02/14/2002DE10034375A1 Production of alcoholic dispersion containing beta-carotene (I), for human food, food supplement or medicament, e.g. egg, nut-nougat or cafe creme liqueur, uses alcohol containing anisole giving turbidity on dilution with water
02/14/2002DE10031043A1 Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung Delayed-release preparations of quinolone antibiotics and methods for their preparation
02/14/2002CA2775616A1 Salts of benzimidazole compound and application thereof
02/14/2002CA2774959A1 Method of using diketopiperazines and composition containing them
02/14/2002CA2634715A1 6.alpha.,9.alpha.-difluoro-17.alpha.-[(2-furanylcarboxyl)oxy}-11.beta.-hydroxy-16.alpha-methyl-3-oxo-androsta-1,4-diene-17.beta.carbothioic acids-fluoromethyl ester as an anti-inflammatory agent
02/14/2002CA2569615A1 Nucleic acid binding compounds containing pyrazolo[3,4-d] pyrimidine analogues of purin-2,6-diamine and their uses
02/14/2002CA2555850A1 Methods of treating cancer and the pain associated therewith using endothelin antagonists
02/14/2002CA2504880A1 Polymorphs of zaleplon and methods for the preparation thereof
02/14/2002CA2453907A1 Association of sim2 with cancer
02/14/2002CA2438446A1 Methods for the preparation of mirtazapine intermediates
02/14/2002CA2420967A1 Heterocyclic compounds as ligands of the gabaa receptor
02/14/2002CA2420066A1 Use, in combination, of a purine activity and a nonsteroidal anti-inflammatory drug for preparing an anti-thrombotic and/or anti-inflammatory drug
02/14/2002CA2419132A1 Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway
02/14/2002CA2419066A1 Food supplement
02/14/2002CA2419060A1 Indole compounds useful for the treatment of cancer
02/14/2002CA2419044A1 Macrolide antibiotics
02/14/2002CA2419042A1 Medicine for fighting against sexual dysfunction
02/14/2002CA2419036A1 Non-imidazole aryloxypiperidines as h3 receptor ligands
02/14/2002CA2419030A1 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods
02/14/2002CA2419027A1 Bicyclic compounds as h3 receptor ligands
02/14/2002CA2418995A1 Lactam compounds and their use as inhibitors of serine proteases and method
02/14/2002CA2418952A1 A novel member of the lysyl oxidase gene family
02/14/2002CA2418951A1 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
02/14/2002CA2418946A1 Pharmaceutical form comprising a cell regulating factor and/or a cell proliferation promoter
02/14/2002CA2418915A1 Stable pergolide mesylate and process for making same
02/14/2002CA2418912A1 Neuroprotective 2-pyridinamine compositions and related methods
02/14/2002CA2418907A1 Hydrogel-driven drug dosage form
02/14/2002CA2418904A1 Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation
02/14/2002CA2418895A1 Biphenyl derivatives and their use as ppar-gamma receptor activators
02/14/2002CA2418832A1 Quinolene derivatives as anti-inflammation agents
02/14/2002CA2418445A1 Stress proteins and peptides and methods of use thereof
02/14/2002CA2418369A1 Non-imidazole aryloxyalkylamines as h3 receptor ligands
02/14/2002CA2418131A1 Peptides capable of functioning as mimotopes for estradiol analytes
02/14/2002CA2418083A1 Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
02/14/2002CA2418023A1 Combinations of dalfopristine/quinupristine with cefpirome
02/14/2002CA2418014A1 Immunotherapy for chronic myelocytic leukemia
02/14/2002CA2417994A1 Synthetic salicylihalamides, apicularens and derivatives thereof
02/14/2002CA2417973A1 Formulations of mometasone and a bronchodilator for pulmonary administration
02/14/2002CA2417967A1 Azabicyclic derivatives and their therapeutic use
02/14/2002CA2417914A1 Cyclic oxyguanidine protease inhibitors
02/14/2002CA2417883A1 Pharmaceutical composition comprising metformin and a 5-phenoxyalkyl-2,4-thiazolidinedione-type derivative
02/14/2002CA2417829A1 Tartrate salts of thiazolidinedione derivative
02/14/2002CA2417828A1 Tartrate salts of thiazolidinedione derivative
02/14/2002CA2417827A1 Tartrate salt of thiazolidinedione derivative
02/14/2002CA2417826A1 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
02/14/2002CA2417818A1 L(+) tartrate salt of thiazolidinedione derivative
02/14/2002CA2417784A1 Pyrrolotriazolopyrimidinone derivatives
02/14/2002CA2417783A1 Solid forms of tin ethyl etiopurpurin and processes for producing such forms
02/14/2002CA2417755A1 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
02/14/2002CA2417606A1 Use of aryl-substituted 1,1-diphosphonates for the treatment of bone diseases
02/14/2002CA2417604A1 Use of essential oils for combating gi tract infection by helicobacter-like organisms
02/14/2002CA2417368A1 Suppressor gene
02/14/2002CA2417358A1 Bio-intermediates for use in the chemical synthesis of polyketides
02/14/2002CA2417225A1 Electro-powder
02/14/2002CA2417214A1 Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
02/14/2002CA2417098A1 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands
02/14/2002CA2416906A1 Synthesis of (r)-3-(4-bromobenzyl)-1-(3,5-dichlorophenyl)-5-iodo-3-methyl-1-h-imidazo[1,2-a]imidazol-2-one
02/14/2002CA2416767A1 Liquid formulation of metformin
02/14/2002CA2416531A1 Compositions for preventing urinary calculus
02/14/2002CA2416525A1 Indole, azaindole and indazole derivatives having vegf inhibiting activity
02/14/2002CA2415469A1 Quinoline derivatives having vegf inhibiting activity
02/14/2002CA2415467A1 Novel n-(2-phenyl-3-aminopropyl)naphtamides
02/14/2002CA2415333A1 Adenovirus e1b-55k single amino acid mutants and methods of use
02/14/2002CA2415022A1 Cinnoline compounds
02/14/2002CA2412368A1 Benzimidazole derivatives, preparation and therapeutic use thereof
02/14/2002CA2411928A1 Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclindependent kinases
02/14/2002CA2406961A1 Cd40 antagonists for use in treating psoriasis and other inflammatory skin conditions
02/14/2002CA2386725A1 Novel pharmaceutical compositions of anti-tubercular drugs and process for their preparation
02/13/2002EP1179533A2 Salt of naphthyridine carboxylic acid derivative
02/13/2002EP1179529A1 Novel hydroxamic acid derivatives
02/13/2002EP1179353A1 Antithrombogenic implants with coating of polyphosphazenes and a pharmacologically active agent
02/13/2002EP1179346A1 Remedies for glomerulosclerosis